Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report
{{output}}
Background: Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role... ...
